SIRT1 is upregulated in cutaneous T-cell lymphoma, and its inhibition induces growth arrest and apoptosis

Cell Cycle

Volumn 13, Issue 4, 2014, Pages 632-640

  Nihal, Minakshi ^a,b   Ahmad, Nihal ^a,b,c   Wood, Gary S ^a,b,c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

Author keywords

Apoptosis; CTCL; HDACI; p53; SIRT1

Indexed keywords

CASPASE 3; CASPASE 9; HISTONE DEACETYLASE INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN P53; SIRTUIN 1; TENOVIN 1; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG; VORINOSTAT; ACETANILIDE DERIVATIVE; ANTINEOPLASTIC AGENT; FORKHEAD TRANSCRIPTION FACTOR; FOXO3 PROTEIN, HUMAN; HISTONE DEACETYLASE; HYDROXAMIC ACID; SIRT1 PROTEIN, HUMAN; TENOVIN-1; THIOUREA;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL METABOLISM; CELL PROLIFERATION; CELL STRAIN HEK293; CELL VIABILITY; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; ENZYME ACTIVITY; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; PROTEIN EXPRESSION; UPREGULATION; WILD TYPE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ACETANILIDES; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FORKHEAD TRANSCRIPTION FACTORS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; LYMPHOMA, T-CELL, CUTANEOUS; SIRTUIN 1; THIOUREA; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84896871202     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.27523     Document Type: Article

References (50)

1. Dai Y, Faller DV. Transcription Regulation by Class III Histone Deacetylases (HDACs)-Sirtuins. Transl Oncogenomics 2008; 3:53-65; PMID:21566744
2. Hagelkruys A, Sawicka A, Rennmayr M, Seiser C. The biology of HDAC in cancer: the nuclear and epigenetic components. Handb Exp Pharmacol 2011; 206:13-37; PMID:21879444; http://dx.doi.org/10.1007/978-3-642-21631-2-2
3. Johnsson AE, Wright AP. The role of specific HAT-HDAC interactions in transcriptional elongation. Cell Cycle 2010; 9:467-71; PMID:20081370; http://dx.doi.org/10.4161/cc.9.3.10543
4. Mehnert JM, Kelly WK. Histone deacetylase inhibitors: biology and mechanism of action. Cancer J 2007; 13:23-9; PMID:17464243; http://dx.doi.org/ 10.1097/PPO.0b013e31803c72ba
5. Rice KL, Hormaeche I, Licht JD. Epigenetic regulation of normal and malignant hematopoiesis. Oncogene 2007; 26:6697-714; PMID:17934479; http://dx.doi.org/10.1038/sj.onc.1210755
6. Peserico A, Simone C. Physical and functional HAT/HDAC interplay regulates protein acetylation balance. J Biomed Biotechnol 2011; 2011:371832; PMID:21151613; http://dx.doi.org/10.1155/2011/371832
7. Schneider G, Krämer OH, Schmid RM, Saur D. Acetylation as a transcriptional control mechanism-HDACs and HATs in pancreatic ductal adenocarcinoma. J Gastrointest Cancer 2011; 42:85-92; PMID:21271301; http://dx.doi.org/10.1007/s12029-011-9257-1
8. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007; 109:31-9; PMID:16960145; http://dx.doi.org/10.1182/blood- 2006-06-025999
9. Duvic M, Vu J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs 2007; 16:1111-20; PMID:17594194; http://dx.doi.org/10.1517/13543784.16.7.1111
10. Duvic M, Olsen EA, Breneman D, Pacheco TR, Parker S, Vonderheid EC, Abuav R, Ricker JL, Rizvi S, Chen C, et al. Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma. Clin Lymphoma Myeloma 2009; 9:412-6; PMID:19951879; http://dx.doi.org/10.3816/CLM.2009.n.082
11. Rangwala S, Zhang C, Duvic M. HDAC inhibitors for the treatment of cutaneous T-cell lymphomas. Future Med Chem 2012; 4:471-86; PMID:22416775; http://dx.doi.org/10.4155/fmc.12.6
12. Sato A. Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects. Onco Targets Ther 2012; 5:67-76; PMID:22573938; http://dx.doi.org/10.2147/OTT.S23874
13. Zhang C, Richon V, Ni X, Talpur R, Duvic M. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol 2005; 125:1045-52; PMID:16297208; http://dx.doi.org/10.1111/j.0022-202X.2005.23925.x
14. Frye R, Myers M, Axelrod KC, Ness EA, Piekarz RL, Bates SE, Booher S. Romidepsin: a new drug for the treatment of cutaneous T-cell lymphoma. Clin J Oncol Nurs 2012; 16:195-204; PMID:22459529; http://dx.doi.org/10.1188/12.CJON. 195-204
15. Haigentz M Jr., Kim M, Sarta C, Lin J, Keresztes RS, Culliney B, Gaba AG, Smith RV, Shapiro GI, Chirieac LR, et al. Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer. Oral Oncol 2012; 48:1281-8; PMID:22748449; http://dx.doi.org/10. 1016/j.oraloncology.2012.05.024
16. Kim M, Thompson LA, Wenger SD, O'Bryant CL. Romidepsin: a histone deacetylase inhibitor for refractory cutaneous T-cell lymphoma. Ann Pharmacother 2012; 46:1340-8; PMID:22968522; http://dx.doi.org/10.1345/aph.1R036
17. Prince HM, Dickinson M. Romidepsin for cutaneous T-cell lymphoma. Clin Cancer Res 2012; 18:3509-15; PMID:22535155; http://dx.doi.org/10.1158/1078-0432. CCR-11-3144
18. Stutz N, Johnson RD, Wood GS. The Fas apoptotic pathway in cutaneous T-cell lymphomas: frequent expression of phenotypes associated with resistance to apoptosis. J Am Acad Dermatol 2012; 67:e1-10; PMID:22884443
19. Nevala H, Karenko L, Vakeva L, Ranki A. Proapoptotic and antiapoptotic markers in cutaneous T-cell lymphoma skin infiltrates and lymphomatoid papulosis. Br J Dermatol 2001; 145:928-37; PMID:11899146; http://dx.doi.org/10. 1046/j.1365-2133.2001.04523.x
20. Ni X, Zhang C, Talpur R, Duvic M. Resistance to activation-induced cell death and bystander cytotoxicity via the Fas/Fas ligand pathway are implicated in the pathogenesis of cutaneous T cell lymphomas. J Invest Dermatol 2005; 124:741-50; PMID:15816832; http://dx.doi.org/10.1111/j.0022-202X.2005.23657.x
21. Vermeer MH, van Doorn R, Dukers D, Bekkenk MW, Meijer CJ, Willemze R. CD8+ T cells in cutaneous T-cell lymphoma: expression of cytotoxic proteins, Fas Ligand, and killing inhibitory receptors and their relationship with clinical behavior. J Clin Oncol 2001; 19:4322-9; PMID:11731515
22. Contassot E, French LE. Targeting apoptosis defects in cutaneous T-cell lymphoma. J Invest Dermatol 2009; 129:1059-61; PMID:19369931; http://dx.doi.org/10.1038/jid.2009.14
23. Wu J, Wood GS. Reduction of Fas/CD95 promoter methylation, upregulation of Fas protein, and enhancement of sensitivity to apoptosis in cutaneous T-cell lymphoma. Arch Dermatol 2011; 147:443-9; PMID:21173302; http://dx.doi.org/10. 1001/archdermatol.2010.376
24. Wu J, Nihal M, Siddiqui J, Vonderheid EC, Wood GS. Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation. J Invest Dermatol 2009; 129:1165-73; PMID:18923451; http://dx.doi.org/10.1038/jid.2008.309
25. Carafa V, Nebbioso A, Altucci L. Sirtuins and disease: the road ahead. Front Pharmacol 2012; 3:4; PMID:22319497; http://dx.doi.org/10.3389/fphar.2012. 00004
26. Houtkooper RH, Pirinen E, Auwerx J. Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol Cell Biol 2012; 13:225-38; PMID:22395773
27. Zschoernig B, Mahlknecht U. SIRTUIN 1: regulating the regulator. Biochem Biophys Res Commun 2008; 376:251-5; PMID:18774777; http://dx.doi.org/10.1016/j. bbrc.2008.08.137
28. Saunders LR, Verdin E. Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene 2007; 26:5489-504; PMID:17694089; http://dx.doi.org/10.1038/sj.onc.1210616
29. Byles V, Chmilewski LK, Wang J, Zhu L, Forman LW, Faller DV, Dai Y. Aberrant cytoplasm localization and protein stability of SIRT1 is regulated by PI3K/IGF-1R signaling in human cancer cells. Int J Biol Sci 2010; 6:599-612; PMID:20941378; http://dx.doi.org/10.7150/ijbs.6.599
30. Bosch-Presegué L, Vaquero A. The dual role of sirtuins in cancer. Genes Cancer 2011; 2:648-62; PMID:21941620; http://dx.doi.org/10.1177/ 1947601911417862
31. Deng CX. SIRT1, is it a tumor promoter or tumor suppressor? Int J Biol Sci 2009; 5:147-52; PMID:19173036; http://dx.doi.org/10.7150/ijbs.5.147
32. Lain S, Hollick JJ, Campbell J, Staples OD, Higgins M, Aoubala M, McCarthy A, Appleyard V, Murray KE, Baker L, et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 2008; 13:454-63; PMID:18455128; http://dx.doi.org/10.1016/j.ccr.2008.03.004
33. Olmos Y, Brosens JJ, Lam EW. Interplay between SIRT proteins and tumour suppressor transcription factors in chemotherapeutic resistance of cancer. Drug Resist Updat 2011; 14:35-44; PMID:21195657; http://dx.doi.org/10.1016/j.drup. 2010.12.001
34. Lamprecht B, Kreher S, Möbs M, Sterry W, Dörken B, Janz M, Assaf C, Mathas S. The tumour suppressor p53 is frequently nonfunctional in Sézary syndrome. Br J Dermatol 2012; 167:240-6; PMID:22384858; http://dx.doi.org/10.1111/j.1365-2133.2012.10918.x
35. Cheng J, Haas M. Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines. Mol Cell Biol 1990; 10:5502-9; PMID:2144611
36. Jang KY, Hwang SH, Kwon KS, Kim KR, Choi HN, Lee NR, Kwak JY, Park BH, Park HS, Chung MJ, et al. SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma. Am J Surg Pathol 2008; 32:1523-31; PMID:18724249; http://dx.doi.org/10.1097/PAS.0b013e31816b6478
37. Kozako T, Aikawa A, Shoji T, Fujimoto T, Yoshimitsu M, Shirasawa S, Tanaka H, Honda S, Shimeno H, Arima N, et al. High expression of the longevity gene product SIRT1 and apoptosis induction by sirtinol in adult T-cell leukemia cells. Int J Cancer 2012; 131:2044-55; PMID:22322739; http://dx.doi.org/10.1002/ ijc.27481
38. Lane DP, Cheok CF, Lain S. p53-based cancer therapy. Cold Spring Harb Perspect Biol 2010; 2:a001222; PMID:20463003; http://dx.doi.org/10.1101/ cshperspect.a001222
39. Giannakou ME, Partridge L. The interaction between FOXO and SIRT1: tipping the balance towards survival. Trends Cell Biol 2004; 14:408-12; PMID:15308206; http://dx.doi.org/10.1016/j.tcb.2004.07.006
40. Huang H, Tindall DJ. Dynamic FoxO transcription factors. J Cell Sci 2007; 120:2479-87; PMID:17646672; http://dx.doi.org/10.1242/jcs.001222
41. Lam M, Carmichael AR, Griffiths HR. An aqueous extract of Fagonia cretica induces DNA damage, cell cycle arrest and apoptosis in breast cancer cells via FOXO3a and p53 expression. PLoS One 2012; 7:e40152; PMID:22761954; http://dx.doi.org/10.1371/journal.pone.0040152
42. Yu J, Zhang L. PUMA, a potent killer with or without p53. Oncogene 2008; 27(Suppl 1):S71-83; PMID:19641508; http://dx.doi.org/10.1038/onc.2009.45
43. Hikisz P, Kiliańska ZM. PUMA, a critical mediator of cell death-one decade on from its discovery. Cell Mol Biol Lett 2012; 17:646-69; PMID:23001513; http://dx.doi.org/10.2478/s11658-012-0032-5
44. Schuler M, Green DR. Mechanisms of p53-dependent apoptosis. Biochem Soc Trans 2001; 29:684-8; PMID:11709054; http://dx.doi.org/10.1042/BST0290684
45. Nolan L, Johnson PW, Ganesan A, Packham G, Crabb SJ. Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential? Br J Cancer 2008; 99:689-94; PMID:18728657; http://dx.doi.org/10.1038/sj.bjc.6604557
46. Samimi S, Morrissey K, Anshelevich S, Evans K, Gardner J, Musiek A, Vittorio C, Rook A, Kim E. Romidepsin and interferon gamma: a novel combination for refractory cutaneous T-cell lymphoma. J Am Acad Dermatol 2013; 68:e5-6; PMID:23244387; http://dx.doi.org/10.1016/j.jaad.2011.06.043
47. Zhang X, Han S, Kang Y, Guo M, Hong S, Liu F, Fu S, Wang L, Wang QX. SAHA, an HDAC inhibitor, synergizes with tacrolimus to prevent murine cardiac allograft rejection. Cell Mol Immunol 2012; 9:390-8; PMID:22922441; http://dx.doi.org/10.1038/cmi.2012.28
48. Wu J, Siddiqui J, Nihal M, Vonderheid EC, Wood GS. Structural alterations of the FAS gene in cutaneous T-cell lymphoma (CTCL). Arch Biochem Biophys 2011; 508:185-91; PMID:21036138; http://dx.doi.org/10.1016/j.abb.2010.10.020
49. Nihal M, Stutz N, Schmit T, Ahmad N, Wood GS. Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis. Cell Cycle 2011; 10:1303-11; PMID:21436619; http://dx.doi.org/10.4161/cc.10.8.15353
50. Schmit TL, Nihal M, Ndiaye M, Setaluri V, Spiegelman VS, Ahmad N. Numb regulates stability and localization of the mitotic kinase PLK1 and is required for transit through mitosis. Cancer Res 2012; 72:3864-72; PMID:22593191; http://dx.doi.org/10.1158/0008-5472.CAN-12-0714